- Safety finding weighs on Pfizer's inflammation drug, and could spell trouble for othersby Jacob Bell on Gennaio 27, 2021 at 5:16 pm
A large safety study found that patients given Pfizer's Xeljanz had health issues like major heart complications and cancer at a higher rate than those who got a different kind of anti-inflammation drug.
- Lilly allies with Vir, GSK as coronavirus variants raise worries about antibody drugsby Ben Fidler on Gennaio 27, 2021 at 5:06 pm
The emergence of new variants has made antibody drug combinations, which are harder for the virus to evade, more important and led to a unique partnership between a trio of drugmakers.
- US to order 200M more doses of Pfizer, Moderna coronavirus vaccinesby Kristin Jensen on Gennaio 27, 2021 at 4:33 pm
As coronavirus variants spread, the White House aims to up U.S. vaccine supply by exercising purchase options in contracts with Pfizer and Moderna.
- Eli Lilly teams up with pharma rival GSK and partner Vir for COVID-19 antibody cocktail testby Ben Adams on Gennaio 27, 2021 at 1:48 pm
Eli Lilly teams up with pharma rival GSK and partner Vir for COVID-19 antibody cocktail test badams Wed, 01/27/2021 - 08:48
- Vir stock soars on blinded, 8-subject hepatitis B analysisby Nick Paul on Gennaio 27, 2021 at 1:13 pm
Vir stock soars on blinded, 8-subject hepatitis B analysis ntaylor Wed, 01/27/2021 - 08:13
- Cancer drug derived from sea squirts outperforms remdesivir in COVID-19 preclinical modelsby Angus Liu on Gennaio 27, 2021 at 12:53 pm
Cancer drug derived from sea squirts outperforms remdesivir in COVID-19 preclinical models aliu Wed, 01/27/2021 - 07:53
- Agios readies FDA filing as anemia drug clears another phase 3by Nick Paul on Gennaio 27, 2021 at 11:55 am
Agios readies FDA filing as anemia drug clears another phase 3 ntaylor Wed, 01/27/2021 - 06:55
- Single-Cell Sequencing: Paving the Way for Precision Medicineby Timothé Cynober on Gennaio 27, 2021 at 10:30 am
Next-generation sequencing techniques to determine an individual’s unique genetic code gave rise to personalized treatments. Single-cell sequencing is the next step towards making precision medicine more accurate. Each cell in our body is unique. Even genetically identical cells can behave differently in response to a certain treatment. With next-generation sequencing, scientists can study how the average cell within a group behaves. However, this can lead to erroneous conclusions. “It is like population surveys, which tell us the average American family has 1.2 children. That’s useless. That’s not helpful. Not a single family has 1.2 children,” stated Christoph Lengauer, CEO of Celsius Therapeutics, a company that develops precision therapies using machine learning. “Single-cell sequencing, by contrast, can indicate which family has six children, and which has just one and a dog,” Lengauer said. “It’s orders of magnitude more granular.” In recent years, there has been a shift in the technology available to perform single-cell sequencing. The global company Fluidigm used to hold the bulk of the market, The post Single-Cell Sequencing: Paving the Way for Precision Medicine appeared first on Labiotech.eu.
- Care Access Research teams up with AstraZeneca for COVID-19 antibody virtual trial workby Ben Adams on Gennaio 27, 2021 at 9:16 am
Care Access Research teams up with AstraZeneca for COVID-19 antibody virtual trial work badams Wed, 01/27/2021 - 04:16
- BioSpace Launches 2021 Hotbed Maps to Highlight Thriving Life Sciences Clusterson Gennaio 27, 2021 at 12:00 am
See the companies featured in our 2021 maps, explore the territories that are thriving in the life sciences industry, research leading employers and search for relevant jobs on BioSpace.
- J.P. Morgan: Will Biotech’s Virtual 2021 Launch Become the New Reality?on Gennaio 27, 2021 at 12:00 am
At the annual J.P. Morgan conference, the biotech industry launched its encore to a wildly successful 2020 – virtually. And, as is becoming the common scenario, attendees found both pros and cons to our new (temporary?) reality.
- How to Make a New Co-Worker Feel Like a Part of the Teamon Gennaio 27, 2021 at 12:00 am
Use these ways to immediately make the a new co-worker feel at ease.
- UK Offers Genomics Expertise to Help Nations ID New SARS-CoV-2 Variantson Gennaio 27, 2021 at 12:00 am
On Tuesday, the U.K. offered its genomics expertise to identify emerging variants of the SARS-CoV-2 virus to countries that lack the resources to make such identifications.
- UPDATE: Bomb Threat Forces Evacuation of AstraZeneca COVID-19 Vaccine Manufacturing Planton Gennaio 27, 2021 at 12:00 am
Police have sealed off the area, according to the report. Few details were available, but eye witnesses said a robot was investigating a suspicious package found at the plant.
- Money on the Move: January 21-26on Gennaio 27, 2021 at 12:00 am
A brief rundown of who’s raking in cash in the biopharma world.
- Vir and GSK Team Up with Eli Lilly for Double Monoclonal Antibody Studyon Gennaio 27, 2021 at 12:00 am
Vir Biotechnology, Eli Lilly and GlaxoSmithKline struck a three-way collaborative deal to evaluate its investigational monoclonal antibody, VIR-7831, in combination with Lilly’s bamlanivimab in low-risk patients with mild to moderate COVID-19.
- More Positive Data Sets Up Agios' Mitapivat for Regulatory Filings This Yearon Gennaio 27, 2021 at 12:00 am
Agios reported its second positive Phase III readout for small molecule mitapivat to treat pyruvate kinase deficiency, this time meeting its primary endpoint of reduced blood transmission burden.
- Cancer Startup Nuvalent Launches With $50 Million Series A Financingon Gennaio 27, 2021 at 12:00 am
The Series A financing will help fuel Nuvalent’s research and development efforts for a portfolio of innovative small molecule kinase inhibitors for programs in non-small cell lung cancer.
- COVID-19 Vaccines Only Tip of the Iceberg for These Leaderson Gennaio 27, 2021 at 12:00 am
Much of the attention on Pfizer, BioNTech, Moderna, Johnson & Johnson and AstraZeneca for the last few months has been on their COVID-19 vaccine efforts.
- Pfizer’s RA Hopeful Fails to Meet Co-Primary Endpoint in Safety Studyon Gennaio 27, 2021 at 12:00 am
Pfizer announced in a statement on Wednesday that the prespecified non-inferiority criteria for a post-marketing safety study of rheumatoid arthritis (RA) drug XELJANZ® (tofacitinib) were not met.
- News Brief: J&J Could Supply U.S. with 100 Million COVID-19 Vaccine Doses and Moreon Gennaio 27, 2021 at 12:00 am
J&J indicated it will soon release Phase III data and could file for Emergency Use Authorization with the U.S. Food and Drug Administration by the end of the month.
- Sanofi, in unusual move, to help Pfizer, BioNTech make coronavirus vaccine dosesby Ned Pagliarulo on Gennaio 26, 2021 at 6:43 pm
The French drugmaker, having hit delays with its own coronavirus shot, agreed to manufacture over 125 million doses of Pfizer and BioNTech's vaccine for supply in Europe.
- Can new Regeneron, Lilly data move the needle for COVID-19 antibody drugs?by Ben Fidler on Gennaio 26, 2021 at 5:00 pm
The results show that drugs from both companies can help prevent or treat COVID-19 when given at the right time. But that won't mean much if barriers to use remain high.
- J&J says study data on coronavirus vaccine due 'early next week'by Ned Pagliarulo on Gennaio 26, 2021 at 4:30 pm
Results from the large Phase 3 trial are highly anticipated. If proven effective, J&J's shot could provide much-needed reinforcements to a constrained immunization effort.
- Johnson & Johnson's closely watched single-shot COVID-19 vaccine readout 'next week' as CFO sees 'robust data'by Ben Adams on Gennaio 26, 2021 at 1:26 pm
Johnson & Johnson's closely watched single-shot COVID-19 vaccine readout 'next week' as CFO sees 'robust data' badams Tue, 01/26/2021 - 08:26